Vancouver, Canada – Virogin Biotech Ltd. (“Virogin”) is pleased to announce that it has received approval for NRC-IRAP funding on April 22nd, 2016. Virogin Biotech Ltd. specializes in anti-cancer drug research with a focus on oncolytic virology. The National Research Council-Industrial Research Assistance Program (NRC-IRAP) is Canada’s premier innovation assistance program for small and medium-sized enterprises (SMEs). The program’s strategic objectives include providing support to small and medium-sized enterprises in Canada in the development and commercialization of technologies, and collaborating in initiatives within regional and national organizations that support the development and commercialization of technologies by small and medium-sized enterprises.
Starting May 01, 2016, Virogin will gain access to NRC-IRAP funding and support for its proposed research project. The funding will be used to further develop construction of oncolytic viral vectors. With the ongoing support of National Research Council, ViroGin believes it will be able to further enhance its research capacity and fast-track the commercialization of its technology.